Physician profile
Guy Jones
NPI 1073824900
$57,208.80
in general payments reported to CMS, 2019-2025
36 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 88% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,760 · 2020: $443 · 2021: $384 · 2022: $933 · 2023: $24K · 2024: $23K · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $4,851 · Travel and Lodging: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,937.50 |
| Food and Beverage | $4,850.55 |
| Travel and Lodging | $1,150.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $23,597.74 | 2022-2023 | |
| Teleflex LLC | $21,000.84 | 2024 | |
| Novocure INC. | $5,538.57 | 2019-2020 | |
| Varian Medical Systems, INC. | $931.78 | 2019 | |
| Abbvie INC. | $536.78 | 2022-2025 | |
| Telix Pharmaceuticals | $518.14 | 2024-2025 | Illuccix |
| Boston Scientific Corporation | $423.76 | 2020-2025 | Spaceoar Vue System - 10ml, Spaceoar System |
| Siemens Medical Solutions USA, INC. | $417.63 | 2022-2025 | Varian Ethos Treatment Planning, Truebeam, Magnetom Vida |
| Myriad Genetic Laboratories, INC. | $366.00 | 2022-2025 | Prolaris, Myrisk |
| Progenics Pharmaceuticals, INC. | $345.40 | 2023-2025 | Pylarify |
| Janssen Biotech, INC. | $312.60 | 2022-2025 | Erleada |
| Merck Sharp & Dohme LLC | $279.28 | 2019-2025 | Keytruda, Lynparza |
| Isoray, INC | $268.97 | 2019-2021 | |
| Amgen INC. | $251.87 | 2021-2023 | Xgeva, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $246.97 | 2019-2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.